WO2007132205A3 - Vecteur pharmaceutique nanoparticulaire - Google Patents

Vecteur pharmaceutique nanoparticulaire Download PDF

Info

Publication number
WO2007132205A3
WO2007132205A3 PCT/GB2007/001741 GB2007001741W WO2007132205A3 WO 2007132205 A3 WO2007132205 A3 WO 2007132205A3 GB 2007001741 W GB2007001741 W GB 2007001741W WO 2007132205 A3 WO2007132205 A3 WO 2007132205A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical carrier
copolymer
polymer
nanoparticle pharmaceutical
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/001741
Other languages
English (en)
Other versions
WO2007132205A2 (fr
Inventor
Waleed Marouf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Priority to PCT/GB2007/001741 priority Critical patent/WO2007132205A2/fr
Publication of WO2007132205A2 publication Critical patent/WO2007132205A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007132205A3 publication Critical patent/WO2007132205A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un vecteur pharmaceutique nanoparticulaire qui comprend un premier polymère ou copolymère incluant une pluralité de groupements terminaux amino-carboxy, et un second polymère ou copolymère. De façon préférentielle, le second polymère ou copolymère est ramifié ou linéaire. De façon préférentielle, le second polymère ou copolymère inclut une pluralité de groupements terminaux alkyle.
PCT/GB2007/001741 2006-05-13 2007-05-11 Vecteur pharmaceutique nanoparticulaire Ceased WO2007132205A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB2007/001741 WO2007132205A2 (fr) 2006-05-13 2007-05-11 Vecteur pharmaceutique nanoparticulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0609588.9 2006-05-13
PCT/GB2007/001741 WO2007132205A2 (fr) 2006-05-13 2007-05-11 Vecteur pharmaceutique nanoparticulaire

Publications (2)

Publication Number Publication Date
WO2007132205A2 WO2007132205A2 (fr) 2007-11-22
WO2007132205A3 true WO2007132205A3 (fr) 2009-03-05

Family

ID=40394183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001741 Ceased WO2007132205A2 (fr) 2006-05-13 2007-05-11 Vecteur pharmaceutique nanoparticulaire

Country Status (1)

Country Link
WO (1) WO2007132205A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936122A1 (fr) * 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Procédés et compositions pour l'administration localisée d'un agent
TWI663991B (zh) * 2016-03-23 2019-07-01 中央研究院 薄殼聚合物奈米粒子及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041613A2 (fr) * 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticules destinees au traitement de cellules hepatomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041613A2 (fr) * 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticules destinees au traitement de cellules hepatomes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KEEGAN M.E. ET AL: "Biodegradable Microspheres with Enhanced Capacity for Covalently Bound Surface Ligands", MACROMOLECULES, vol. 37, 2004, pages 9779 - 9784, XP002498493 *
MCCARRON PAUL A ET AL: "Antibody conjugates and therapeutic strategies.", MOLECULAR INTERVENTIONS DEC 2005, vol. 5, no. 6, December 2005 (2005-12-01), pages 368 - 380, XP002498492, ISSN: 1534-0384 *
MO ET AL: "Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 108, no. 2-3, 28 November 2005 (2005-11-28), pages 244 - 262, XP005163068, ISSN: 0168-3659 *
MO ET AL: "Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 107, no. 1, 20 September 2005 (2005-09-20), pages 30 - 42, XP005064058, ISSN: 0168-3659 *
NOBS L ET AL: "Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin(TM) for active targeting", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 58, no. 3, 1 November 2004 (2004-11-01), pages 483 - 490, XP004586428, ISSN: 0939-6411 *
TRACY M A ET AL: "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro", BIOMATERIALS 199906 GB, vol. 20, no. 11, June 1999 (1999-06-01), pages 1057 - 1062, XP002498494, ISSN: 0142-9612 *

Also Published As

Publication number Publication date
WO2007132205A2 (fr) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2008094834A3 (fr) Supports de médicament multifonctionnels
WO2008100346A3 (fr) Monomères et polymères n-substitués
WO2011130694A3 (fr) Polymères de haut poids moléculaire contenant des zwitterions
WO2007081991A3 (fr) Nouveaux materiaux conjugues dotes d’unites proquinoidales
MX2007012157A (es) Micelas polimericas para suministro de farmacos.
WO2008137235A3 (fr) Dispositifs médicaux implantables fabriqués à partir de polymères avec des groupes radio-opaques
ATE547129T1 (de) Multimodale formgedächtnis-polymere
WO2010026433A3 (fr) Matériau polymère
WO2008141110A3 (fr) Conjugués de polyglutamate et conjugués de polyglutamate-amino acide contenant une pluralité de médicaments
WO2008124735A3 (fr) Supports de médicaments multifonctionnels à base de polyglutamate
WO2008144392A3 (fr) Dispositifs médicaux anti-dépôt
WO2011057219A3 (fr) Hydrogels zwitterioniques réticulés
WO2010019718A3 (fr) Nanoparticules de support et compositions, procédés et systèmes apparentés
WO2005101983A3 (fr) Systeme a retention gastrique
WO2005072371A3 (fr) Sucres polymeres ramifies et leurs nucleotides
GB2453457A (en) Indenofluorene polymer based organic semiconductor materials
DE602007009388D1 (de) Implantierbare medizinprodukte aus verzweigten polymeren
EP2465548A3 (fr) Films polymères implantables
GEP20156230B (en) Forms of rifaximin and usage thereof
EP2767288A3 (fr) Adhésif et hydrogel biopolymères imités
WO2008115694A3 (fr) Polymérisation d'azides multifonctionnels et polymères dérivés de ceux-ci
WO2008005371A3 (fr) Polymères de poly(orthoester) et leurs procédés de préparation et d'utilisation
GB2475667A (en) Polymers derived from bis (thienocyclopenta) benzothiadiazole and their use as organic semiconductors
EP2133382A4 (fr) Polymère, et film ou feuille le comprenant
WO2010129316A3 (fr) Compositions cosmetiques comprenant des cyanodiphenylacrylates et des polymeres filmogenes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732767

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 0609588.9

Country of ref document: GB

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

122 Ep: pct application non-entry in european phase

Ref document number: 07732767

Country of ref document: EP

Kind code of ref document: A2